Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
Avelo Airlines to End DHS Deportation Flights and Close Arizona Base Amid Rising Costs 
Singapore GDP Growth Surges in 2025 but Outlook Remains Cautious Amid Global Trade Risks 
U.S. Dollar Slides Toward Biggest Annual Loss Since 2017 as 2026 Risks Loom 
Japanese Business Leaders Urge Government Action as Weak Yen Strains Economy 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
South Korea Exports Hit Record High as Global Trade Momentum Builds 
Oil Prices Slip Slightly as Markets Weigh Geopolitical Risks and Supply Glut Concerns 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
China Manufacturing PMI Rebounds in December, Offering Boost to Economic Growth Outlook 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
China Imposes 55% Tariff on Beef Imports Above Quota to Protect Domestic Industry 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Moderna has assigned its new chief medical officer after recruiting a former Johnson & Johnson executive. It was reported that effective on July 6, Dr. Paul Burton will be joining the American pharmaceutical and biotechnology company based in Cambridge, Massachusetts.
As per Market Watch, Dr. Burton worked in Janssen Pharmaceuticals as its chief global medical affairs officer from March 2020, but he has been with Johnson & Johnson for 16 years and held various executive positions during his tenure.
Burton moves to Moderna
Dr. Paul Burton will be replacing Tal Zaks, who is said to be leaving Moderna after six years with the company. The incoming Moderna medical chief was also said to have previously worked as the vice president and head of cardiovascular and metabolic medical affairs in J&J.
He will be joining the biotech firm at the time when it is seeking approval from the government’s health regulators so that its COVID-19 vaccine could be used for adolescents too. Moderna’s chief executive officer, Stephane Bancel, said that testing results for the use of the vaccine in children will be available by fall. If the outcome is good, she said that it could help get a nod from the regulators and health safety boards.
“Paul’s extensive medical experience in the global pharmaceutical and biotech industry will be important to Moderna as we expand internationally and continue our journey as a commercial company,” CEO Bancel said in a press release. “As we work to deliver on the promise of mRNA science to create a new generation of transformative medicines for patients, Paul’s expertise across multiple therapeutic areas and his proven track record leveraging data science and digital technologies to reimagine medical engagement will be invaluable.”
Moderna’s foray into COVID-19 vaccine production
Moderna’s name became popular after joining the list of pharmaceutical firms that develop and produce vaccines for COVID-19. Its label was often in the headlines since last year, and now it is considered as one of the leading suppliers of vaccines worldwide.
Moderna’s CEO believes that with Dr. Paul Burton’s expertise, the company will achieve more of its goals in the coming years. She said that she is really looking forward to working with the new medical chief as they could achieve many things together.
